Prometic Life Sciences announced PBI-4050, its orally-active drug candidate PBI-4050, received a Promising Innovative Medicine designation by the UK Medicines and Healthcare Products Regulatory Agency.
Prometic Life Sciences announced it closed an $80 million line of credit with Structured Alpha LP.
Prometic Life Sciences shared new interim data from six-month clinical data from its ongoing pivotal IVIG Phase 3 clinical trial in patients suffering from primary immunodeficiencies.
Prometic Life Sciences announced it received approval for a phase 2 clinical trial by the Swedish Medical Products Agency.
Prometic Life Sciences entered into a binding letter of intent to secure a USD $80 million line of credit from Structured Alpha LP.
Prometic Life Sciences announced it received a priority review status from Health Canada regarding its new drug submission for its plasminogen replacement therapy.
Shares of ProMetic Life Sciences were on the rise on Monday thanks to FDA approval for their planned phase 2 and 3 trials of PBI-4050.
Prometic Life Sciences announced the US Food and Drug Administration granted a Rare Pediatric Disease Designation to Prometic’s Ryplazimä.
Prometic Life Sciences announced new data from its Phase 2/3 trial of Ryplazym in patients with congenital plasminogen deficiency.
Prometic Life Sciences closes equity offering for gross proceeds of $61.7 million.
Prometic Life Sciences shared their unaudited financial results for the first quarter of 2017.
Prometic Life Sciences will present new data on the benefits of plasminogen administration to reduce lung injury in animal model associated with acute pancreatitis.
Prometic Life Sciences received a $9.5 million purchase order for affinity resin supply to an established client.